GlassScriptPhysician profile
Richard Moody
NPI 1457325862
$10,479.67
in general payments reported to CMS, 2019-2025
51 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,029 · 2020: $932 · 2021: $1,852 · 2022: $1,429 · 2023: $1,397 · 2024: $1,649 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,636.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,049.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $877.61 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $757.70 | 2019-2025 | |
| Amarin Pharma, INC. | $519.68 | 2019-2022 | |
| Abbott Laboratories | $458.42 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amgen INC. | $448.18 | 2019-2024 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $424.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.04 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $386.09 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $343.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $270.08 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $224.17 | 2019-2024 | Veozah |
| Abbvie INC. | $155.87 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $134.84 | 2019-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Moody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.